Merck & Co. Inc. (MRK)

71.10
NYSE : Health Technology
Prev Close 70.78
Day Low/High 70.91 / 71.58
52 Wk Low/High 52.83 / 71.58
Avg Volume 7.94M
Exchange NYSE
Shares Outstanding 2.66B
Market Cap 188.24B
EPS 0.90
P/E Ratio 141.56
Div & Yield 1.92 (2.73%)
Biotech and Broadway Come Together to Fight Cancer

Biotech and Broadway Come Together to Fight Cancer

Cancer affects all of us. But the Damon Runyon Cancer Research Foundation has invested $330 million (and counting) in research to fight it. We spent time with its first female CEO to hear about her journey and how immunotherapies are taking the lead.

A Bullish Options Play on Allergan

A Bullish Options Play on Allergan

Buyout rumors aside, AGN is a name I still find attractive.

Merck Receives Positive CHMP Opinion For DELSTRIGO™ (doravirine/lamivudine/tenofovir Disoproxil Fumarate) And PIFELTRO™ (doravirine) In The European Union For The Treatment Of HIV-1 Infection

Merck Receives Positive CHMP Opinion For DELSTRIGO™ (doravirine/lamivudine/tenofovir Disoproxil Fumarate) And PIFELTRO™ (doravirine) In The European Union For The Treatment Of HIV-1 Infection

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending granting of marketing...

Merck Publishes Corporate Responsibility Report

Merck Publishes Corporate Responsibility Report

Report Illustrates How Merck Creates Sustainable Value for Business and Society

Merck and PPL Corp. Still Look Good Here

Both names have enjoyed recent price run-ups and continue to pay decent dividends.

BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival In Previously Untreated Patients With Advanced Renal Cell Carcinoma In Phase III Study

BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival In Previously Untreated Patients With Advanced Renal Cell Carcinoma In Phase III Study

DARMSTADT, Germany and NEW YORK, Sept. 11, 2018 /PRNewswire/ -- Not intended for UK-based media First positive Phase III immunotherapy trial in combination with a tyrosine kinase inhibitor (TKI) in any tumor type Results significant in PDL1+ and all-comer...

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) In Combination With Pemetrexed And Platinum Chemotherapy For The First-Line Treatment Of Patients With Metastatic Nonsquamous NSCLC, With No EGFR Or ALK Genomic Tumor Aberrations

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) In Combination With Pemetrexed And Platinum Chemotherapy For The First-Line Treatment Of Patients With Metastatic Nonsquamous NSCLC, With No EGFR Or ALK Genomic Tumor Aberrations

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA, the company's anti-PD-1 therapy, in combination with pemetrexed (ALIMTA ®) and platinum chemotherapy for the...

Merck To Present At The Morgan Stanley 16th Annual Global Healthcare Conference

Merck To Present At The Morgan Stanley 16th Annual Global Healthcare Conference

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Kenneth C.

Data From Merck's Leading Lung Cancer Research Program With KEYTRUDA® (pembrolizumab) To Be Presented At IASLC 19th World Conference On Lung Cancer

Data From Merck's Leading Lung Cancer Research Program With KEYTRUDA® (pembrolizumab) To Be Presented At IASLC 19th World Conference On Lung Cancer

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that investigational data from the company's leading lung cancer research program with KEYTRUDA, Merck's anti-PD-1 therapy, will be presented at the IASLC 19th World...

FDA Grants Priority Review To Merck's Supplemental Biologics License Application For KEYTRUDA® (pembrolizumab) For The Treatment Of Merkel Cell Carcinoma, A Rare Form Of Skin Cancer

FDA Grants Priority Review To Merck's Supplemental Biologics License Application For KEYTRUDA® (pembrolizumab) For The Treatment Of Merkel Cell Carcinoma, A Rare Form Of Skin Cancer

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.

Broker Darlings Of The Dow: Merck Ranks As A Top 15 Analyst Pick

Broker Darlings Of The Dow: Merck Ranks As A Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Merck & Co Inc is the #10 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Merck & Co Inc also comes in above the median of analyst picks among the broader S&P 500 index components, claiming the #112 spot out of 500.

The New #14 Most Shorted Dow Component: Merck

The New #14 Most Shorted Dow Component: Merck

The most recent short interest data has been released for the 08/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Why Large-Cap Pharma Stocks Like Pfizer and Lilly Might Still Have Upside

Why Large-Cap Pharma Stocks Like Pfizer and Lilly Might Still Have Upside

A 'bullish perfect storm of technical factors' is powering the recent strength in large-cap pharma stocks, says Evercore ISI's Rich Ross.

Here's Why You Should Invest in Immunotherapy Companies

Here's Why You Should Invest in Immunotherapy Companies

Immunotherapy may be the future of fighting cancer and companies are racing to capitalize on that. We spoke with the CEO of the Damon Runyon Cancer Research Foundation to find out why.

Eisai And Merck Announce European Commission Grants Marketing Authorization For LENVIMA® (lenvatinib) As First-Line Treatment In Adults With Advanced Or Unresectable Hepatocellular Carcinoma

Eisai And Merck Announce European Commission Grants Marketing Authorization For LENVIMA® (lenvatinib) As First-Line Treatment In Adults With Advanced Or Unresectable Hepatocellular Carcinoma

Eisai and Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the European Commission (EC) has granted a marketing authorization for the oral receptor tyrosine kinase (RTK) inhibitor LENVIMA ® (lenvatinib), as a...

Drug Companies Start Keeping Prices in Check to Avoid Government Crackdown

Drug Companies Start Keeping Prices in Check to Avoid Government Crackdown

The industry has taken to smaller, voluntary measures to avoid serious federal action on pricing.

Jim Cramer: What Does Politics Have to Do With Johnson & Johnson's P/E?

Jim Cramer: What Does Politics Have to Do With Johnson & Johnson's P/E?

The answer is plenty, but you can't trade that.

Merck Could Suffer a Downward Correction to Unwind the Overbought Conditions

Merck Could Suffer a Downward Correction to Unwind the Overbought Conditions

Merck is vey overbought on a number of time frames.

Merck Shares Slip Despite 'Milestone' Lung Cancer Drug Approval

Merck Shares Slip Despite 'Milestone' Lung Cancer Drug Approval

Merck shares retreat as regulatory approval ramps up speculation.

Jim Cramer: This Is a Rotation, Not a Recession

Jim Cramer: This Is a Rotation, Not a Recession

There's too much evidence of economic strength, so don't interpret these moves as a sign of a real slowdown.

Family Offices Inject Capital Into Budding Cannabis Industry

Family Offices Inject Capital Into Budding Cannabis Industry

Family offices, which manage billions of dollars and have much fewer restrictions on how they deploy capital, have been wading into the cannabis space with increasing frequency.

Healthy Interactions And Merck Announce Launch Of Digital Health Platform Designed To Enhance Patient Engagement In Diabetes Management

Healthy Interactions And Merck Announce Launch Of Digital Health Platform Designed To Enhance Patient Engagement In Diabetes Management

Map4health™ Offers Accessible, Direct Communications Platform Between Diabetes Patients and Educators

Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-Line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)

Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-Line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)

- Approval was based on REFLECT, the first-ever positive Phase 3 trial against an active comparator in previously untreated patients with unresectable HCC

Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)

Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)

- Approval was based on REFLECT, the first-ever positive Phase 3 trial against an active comparator in previously untreated patients with unresectable HCC

Why One Money Manager Is Telling Clients to Raise Cash Right Now

Why One Money Manager Is Telling Clients to Raise Cash Right Now

Time to brace for a summer pullback?

Merck Becomes #17 Most Shorted Dow Stock, Replacing Travelers Companies

Merck Becomes #17 Most Shorted Dow Stock, Replacing Travelers Companies

The most recent short interest data has been released for the 07/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

TheStreet Quant Rating: B+ (Buy)